The purpose of this study is to investigate the clinical effect of oral vitamin D supplement in patients with psoriasis. Psoriasis,
Conditions
Interventions
Patients in vitamin D2 group received vitamin D2 60,
000 IU every 2 weeks for 6 months. The 60,
000 IU every two weeks dose was chosen as it approximates to 4,
000 IU/day which the safety tolerable upper limits of vitamin D were 4,
000-
000 IU/day according to the IOM and Endocrine Society recommendation.,Patients in placebo group received similar-
looking placebo pills every 2 weeks for 6 months.
Experimental Drug,Placebo Comparator Drug
Oral vitamin D2,Placebo
Sponsors
Thammasat University
None (Thammasat University was the sole sponser for this trial)
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients with chronic stable plaque type psoriasis, aged 18-70 years (both men and women), mild psoriasis evaluated by using Psoriasis Area and Severity Index (PASI) score (PASI < 10), and no change of the psoriatic medication during study period
Exclusion criteria
Exclusion criteria: Currently on systemic therapy or phototherapy or last episodes within 30 days before enrollment, hepatic impairment, renal impairment, cancer, receiving immunosuppressive medication or chemotherapy, receiving vitamin D, calcium supplement, bisphosphonate, antiepileptic agents, anticoagulants, history of hypercalcemia, nephrolithiasis, parathyroid disease, pregnancy, and breastfeeding woman
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The improvement of Psoriasis Area and Severity Index (PASI) at 3- and 6-months after treatment 0-, 3- and 6-months after treatment Psoriasis Area and Severity Index (PASI) | — |
Secondary
| Measure | Time frame |
|---|---|
| Prevalence of vitamin D deficiency and insufficiency in psoriasis 0-, 3- and 6-months after treatment Prevalence,The improvement of vitamin D deficiency and insufficiency at 3- and 6-months after treatment 0-, 3- and 6-months after treatment serum 25(OH) vitamin D level,Change of serum 25(OH) vitamin D level 0-, 3- and 6-months after treatment Serum 25(OH) vitamin D level,Change of calcium, phosphate, parathyroid hormone, C-reactive protein (CRP) during the study period 0-, 3- and 6-months after treatment Serum calcium, phosphate, parathyroid hormone, C-reactive protein (CRP) | — |
Countries
Thailand
Contacts
Public ContactWareeporn Disphanurat
Dermatology Unit, Department of Internal Medicine, Faculty of Medicine, Thammasat University
Outcome results
None listed